What happened
Director James Healy bought 969,480 shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) at $21.00 each on Oct. 28, for $20.36 million. The shares were bought through four fund vehicles over which he may be deemed to share voting and dispositive power.
Sofinnova Venture Partners XI, L.P. took 952,380 of the shares and now holds 2,815,707. Three SummitTX vehicles took the rest: 6,395 shares through SummitTX Apex SP, 3,772 through SummitTX Alpha SP and 6,933 through SummitTX Pinnacle Master, L.P., which now holds 25,267.
Healy is a managing member of the general partner entities above those funds. The form lists Sofinnova Investments, Inc. in Menlo Park, California as his address. An attorney-in-fact signed it on his behalf Oct. 30.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares bought | 969,480 shares | SEC Form 4 | |
| Purchase price per share | $21.00 | SEC Form 4 | |
| Total purchase value | $20.36 million | SEC Form 4 | |
| Held by Sofinnova Venture Partners XI, L.P. after the buy | 2,815,707 shares | SEC Form 4 | |
| Share of purchase made through Sofinnova Venture Partners XI, L.P. | 98.2% | Calculated from SEC Form 4 |
Read more: Rapport Therapeutics (RAPP) company research
Why it matters
OptimistFi has argued that Rapport is a financing-backed clinical-development option. It pays off if research spending turns into differentiated human data before cash burn forces punitive dilution. A director's funds buying the stock add a backer to that picture, and OptimistFi reads the buy as a modest positive.
One fund drove the purchase. By OptimistFi's calculation, Sofinnova Venture Partners XI took 98.2% of the shares bought, so the signal rests on that fund more than on the three smaller SummitTX vehicles. Healy is reported as a director, not an officer.
All four funds paid the same price on the same day, so the split reflects how many shares each fund took, not a different price.
The buy leaves the main question open. Clinical results, cash needs and any new financing still decide the case. The shares are held indirectly, and Healy disclaims beneficial ownership except to the extent of any pecuniary interest.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Rapport's next quarterly report is the next test. Cash that covers research spending without a new raise would support OptimistFi's view. Faster burn would weaken it. A new equity raise would be the clearest sign that the dilution risk is arriving.
More from OptimistFi
- RAPP stock: research and coverage of Rapport Therapeutics
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
- Perps news: leveraged stocks, gold, FX and crypto on-chain
- Prop firms that fund crypto and stock perps traders: rules, prices and payouts
- Top perps movers today: stocks, commodities, FX and indices
Sources
- SEC Form 4, James Healy, Rapport Therapeutics, Inc. — Statement of changes in beneficial ownership covering transactions dated Oct. 28, 2026, signed by an attorney-in-fact on Oct. 30, 2026.
Explore OptimistFi research on Rapport Therapeutics, Inc.: https://optimistfi.com/stocks/RAPP
Browse Rapport Therapeutics, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the Rapport Therapeutics, Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
